in terms of safer, i think that is the issue. People in the know say this result, if as we hope it to be, sees the chances of the RP11 candidate being successful in the clinical trials rise to about 70%. Given revenues and profits will be of the order of 1 billion US$pa this is quite a bit more that “safer” It should take the company sp past 30c in the short term, but one can never predict what’s fair value in the markets eyes. The fact that it validates the platform and the other 2+ drugs is also not factored into the companies Mcap potential, and may not be in the short term after next weeks results. TH Monday and results released on morning of AGM?
PYC Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)